首页> 外文期刊>Molecular cancer research: MCR >Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation
【24h】

Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation

机译:转移性黑素瘤中的恶性表型受SR-BI的治理及其与糖基化和STAT5活化的关系

获取原文
获取原文并翻译 | 示例
           

摘要

Metastatic melanoma is hallmarked by elevated glycolytic flux and alterations in cholesterol homeostasis. The contribution of cholesterol transporting receptors for the maintenance of a migratory and invasive phenotype is not well defined. Here, the scavenger receptor class B type I (SCARB1/SR-BI), a high-density lipoprotein (HDL) receptor, was identified as an estimator of melanoma progression in patients. We further aimed to identify the SR-BI-controlled gene expression signature and its related cellular phenotypes. On the basis of whole transcriptome analysis, it was found that SR-BI knockdown, but not functional inhibition of its cholesterol-transporting capacity, perturbed the metastasis-associated epithelial-tomesenchymal transition (EMT) phenotype. Furthermore, SR-BI knockdown was accompanied by decreased migration and invasion of melanoma cells and reduced xenograft tumor growth. STAT5 is an important mediator of the EMT process and loss of SR-BI resulted in decreased glycosylation, reduced DNA binding, and target gene expression of STAT5. When human metastatic melanoma clinical specimens were analyzed for the abundance of SR-BI and STAT5 protein, a positive correlation was found. Finally, a novel SR-BI-regulated gene profile was determined, which discriminates metastatic from nonmetastatic melanoma specimens indicating that SR-BI drives gene expression contributing to growth at metastatic sites. Overall, these results demonstrate that SR-BI is a highly expressed receptor in human metastatic melanoma and is crucial for the maintenance of the metastatic phenotype. (C) 2017 AACR.
机译:转移性黑色素瘤是通过升高的糖酵解通量和胆固醇稳态的改变来标记。胆固醇转运受体对维持迁移和侵入性表型的贡献并不明确。这里,清除剂受体B类I(ScarB1 / SR-Bi),高密度脂蛋白(HDL)受体,被鉴定为患者黑素瘤进展的估计。我们进一步旨在鉴定SR-BI控制的基因表达签名及其相关细胞表型。在整个转录组分析的基础上,发现SR-BI敲击,但不能抑制其胆固醇转运能力,扰乱转移相关的上皮 - 断层化转换(EMT)表型。此外,SR-BI敲低伴随着黑素瘤细胞的迁移和侵袭降低,并降低了异种移植肿瘤生长。 STAT5是EMT过程的重要介体,并且SR-BI的丧失导致糖基化降低,降低DNA结合和STAT5的靶基因表达。当分析人类转移性黑色素瘤临床标本时,针对SR-BI和Stat5蛋白的丰度,发现了阳性相关性。最后,测定了一种新的SR-Bi-Currupt基因谱,其区分了非更换黑色素瘤样本的转移性,表明SR-BI驱动基因表达有助于转移位点的生长。总的来说,这些结果表明,SR-BI是人转移性黑色素瘤中的高度表达受体,对维持转移表型至关重要。 (c)2017年AACR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号